Education in Heart (Volume 2)

Cover Page......Page 1
Title Page......Page 2
ISBN 0727916637......Page 3
Contents......Page 4
Citation Index......Page 7
Contributors......Page 8
Introduction......Page 10
SECTION I: CORONARY DISEASE......Page 12
Incidence of failed thrombolysis......Page 14
Diagnosis of failed thrombolysis......Page 15
Timing of diagnosis......Page 17
Management options......Page 18
Future directions......Page 19
Conclusions......Page 20
Advantages of acute coronary angiography......Page 23
Which patients benefit most?......Page 24
Patency of the artery and reperfusion of the myocardium......Page 25
Future developments......Page 26
Why stents?......Page 28
Is the use of stents justified?: clinical trials......Page 29
Dealing with in-stent restenosis......Page 31
Stenting in certain patient subgroups......Page 32
Stenting and areas of contention......Page 33
Future directions......Page 35
SECTION II: HEART FAILURE......Page 38
β Blockers......Page 40
Antiarrhythmic drugs......Page 44
ARB–ACE inhibitor comparison studies......Page 47
ARB–ACE inhibitor combination studies......Page 48
ARB–placebo comparison studies......Page 50
A wider role for RAAS inhibition in CHF?......Page 51
Conclusions and clinical recommendations......Page 52
Correlates of exercise capacity in CHF......Page 54
Exercise training in CHF......Page 56
Conclusions......Page 57
SECTION III: CARDIOMYOPATHY......Page 60
Restrictive cardiomyopathy......Page 62
Differentiating features......Page 63
Conclusions......Page 67
Clinical diagnosis......Page 69
Laboratory investigation......Page 71
Assessment of risk......Page 72
Conclusion......Page 73
SECTION IV: VALVE DISEASE......Page 76
Percutaneous mitral commissurotomy......Page 78
Percutaneous aortic valvuloplasty......Page 82
Conclusion......Page 83
Severity of aortic stenosis......Page 84
Mild aortic stenosis......Page 85
Moderate aortic stenosis......Page 86
Persistent or recurrent fever......Page 89
Role of surgery in the problem patient......Page 91
Microbiology......Page 94
Treatment......Page 95
Surgical reintervention......Page 96
Prophylaxis......Page 97
Prosthetic valve endocarditis......Page 98
Blood culture negative IE......Page 99
Choice of antibiotic for specific pathogens and the need for two agents......Page 100
Antibiotic prophylaxis of IE......Page 101
Late complications after valve surgery......Page 103
SECTION V: ELECTROPHYSIOLOGY......Page 110
Technical considerations......Page 112
Catheter ablation of supraventricular arrhythmias......Page 113
Economic considerations......Page 117
Conclusion......Page 118
Programming and follow up......Page 119
Clinical trials of ICDs......Page 120
Cost effectiveness of ICDs......Page 121
ICD indications......Page 122
Conclusions......Page 123
Sick sinus syndrome......Page 125
Congestive heart failure......Page 126
Hypertrophic cardiomyopathy......Page 128
Conclusions......Page 129
Classification of tachycardias with a broad QRS complex......Page 131
The ECG diagnosis......Page 132
Aetiology of VT......Page 135
Value of the ECG during sinus rhythm......Page 136
Conclusion......Page 137
SECTION VI: CONGENITAL HEART DISEASE......Page 138
Pulmonary to systemic flow ratio (Qp:Qs)......Page 140
Cardiac output and pulmonary blood flow......Page 141
Pulmonary vascular reactivity......Page 144
Valve (orifice) area......Page 146
Outcomes associated with specific cardiac lesions......Page 148
Management......Page 150
Neurally mediated syncopes......Page 154
Investigation of recurrent syncope......Page 155
Management of neurally mediated syncope......Page 156
Cardiac pacing......Page 157
SECTION VII: IMAGING TECHNIQUES......Page 160
Fundamentals of cardiovascular magnetic resonance......Page 162
Current established clinical indications......Page 163
Indications close to clinical reality......Page 167
CMR techniques in development......Page 168
Education in CMR......Page 169
Determining the sources of embolism......Page 171
Infective endocarditis and its complications......Page 173
Intraoperative application......Page 174
Detection of myocardial ischaemia/viability......Page 175
Summary......Page 176
SECTION VIII: GENERAL CARDIOLOGY......Page 178
Myxoma......Page 180
Other benign primary cardiac tumours......Page 182
Malignant primary cardiac tumours......Page 183
Secondary cardiac tumours......Page 184
Biological effects of nitric oxide......Page 185
Endothelial dysfunction in established cardiovascular disease......Page 187
Endothelial dysfunction and risk factors for coronary heart disease......Page 188
Alteration of the L-arginine: nitric oxide pathway in diseases: potential mechanisms......Page 189
Therapeutic possibilities......Page 190
Conclusions......Page 192
Angina and revascularisation in diabetes......Page 194
Acute myocardial infarction in diabetes......Page 195
Heart failure in diabetes......Page 196
Risk factor modification for protecting against coronary heart disease in diabetes......Page 197
Other strategies for protecting against coronary heart disease in diabetes......Page 198
Screening for coronary heart disease in diabetes......Page 199
Pathology and classification......Page 201
Diagnosis and assessment......Page 202
Therapeutic strategy......Page 203
Aortic aneurysm......Page 207
Pathological spectrum of aortic dissection......Page 208
Imaging of aortic dissection......Page 209
Management of aortic dissection......Page 210
Traumatic aortic disease......Page 211
Inherited aortic diseases......Page 212
Conclusions......Page 213
Aetiologic spectrum and prognosis of moderate and large pericardial effusion......Page 215
Clinical clues to aetiology......Page 216
Clinical correlation of echocardiographic and catheterisation findings......Page 217
Idiopathic chronic pericardial effusion......Page 218
Management of neoplastic pericardial effusion......Page 219
Cardiovascular disease in uraemia: natural history and epidemiology......Page 221
Conventional CVD risk factors and patterns of CVD disease......Page 223
Coronary artery disease......Page 225
Ongoing trials......Page 227
Conclusions......Page 228
Bradycardia......Page 229
Investigational procedures......Page 230
Reversibility......Page 231
Sudden death......Page 232
Conclusion......Page 233
Risk factors, epidemiology, and risk stratification......Page 234
Pathophysiology and clinical presentation......Page 235
Diagnostic procedures......Page 237
The integrated diagnostic approach with management options......Page 242
Heparin......Page 246
Direct thrombin inhibitors......Page 249
Thrombolytic treatment......Page 250
Pulmonary embolectomy......Page 252
Oral anticoagulants......Page 253
Treatment of pulmonary embolism in pregnancy......Page 254
The future......Page 255
Location of the heart......Page 256
The echocardiographic windows......Page 257
SECTION IX: HYPERTENSION......Page 262
Long term benefits of treatment......Page 264
Antihypertensive drugs and short term measurement of response......Page 265
A unitary scheme for pathogenesis of hypertension, and implications for rational choice of treatment......Page 266
Investigation and treatment of resistant hypertension: importance of aldosterone......Page 268
Emergency reduction of blood pressure......Page 269
Conclusion......Page 270
Isolated systolic hypertension......Page 272
Pathophysiology......Page 273
Clinical approach to the heart in the patient with hypertension......Page 274
Choice of drug in the hypertensive with concomitant heart disease......Page 278
Summary......Page 279
A......Page 282
C......Page 283
G......Page 284
N......Page 285
S......Page 286
Z......Page 287
Thank you for purchasing Education in Heart Volume II......Page 288